December 2, 2008

Events

To have your event featured here, contact Lynn Cloonan for more information.

Burning Questions

By BIO-IT World

December 15, 2003 | Using or developing open-source software (OSS) raises special questions for biotech organizations. Despite the fact that many answers won't be definitive, organizations should ask the following questions anyway:

Will OSS deliver tools of the required reliability, quality, and robustness?
When the software is involved in a regulated process, will the use of OSS help or hinder compliance approval?
Can the OSS community provide the continuity in vertical products as they have for horizontal products such as the Linux operating system?
How long will the developer community continue to show interest in supporting a particular product, and will it be long enough? Or will the community move on to new products and orphan older ones?
Will the available OSS tools and products provide the degree of reliable security needed for patient and research records?
How is security ensured for OSS products that are constantly evolving?
How do users control the updating of products?
How can a company delivering a product under an open-source license continue to support its users when they keep modifying the software?
Can the widespread use of open-source software in academic research be carried over to the corporate research environment? If not, does that mean universities will encounter difficulties licensing their research tools?

Back to The Hidden Costs of 'Free' Software

White Papers & Special Reports

10 Secrets to Recession-Proof Your Business

Medidata Solutions

Rising Clinical Trial Delays and Costs - Addressing the Cause, Not the Symptoms

Protocol complexity is taking a toll on clinical study speed and efficiency: increasingly complicated and ambitious protocols are not only burdening sites and study volunteers but are also prolonging trials and increasing expenses. In response, sponsors have turned to global study placement, restructured site relationships and new site management practices, but the problem remains.

This podcast will discuss:

Why these responses address only the symptoms, not the underlying cause, of rising clinical trial delays and costs.
Results of a recent joint Tufts University / Medidata Solutions study.
New metrics benchmarking protocol design trends.
Systematic protocol design improvements and why they are essential to clinical trial performance excellence.

Speakers: Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Ed Seguine, General Manager, Trial Planning Solutions at Medidata.

Download Now

More Podcasts

Job Openings

Director, Center For Information Technology (CIT) - National Institutes of Health (NIH), Department of Health and Human Service
Located in Bethesda, MD. This position requires:
• High-level vision, leadership, management, and modernization of CIT programs and services.
• Strategic direction and policy development for CIT long-term operations and objectives.
• Serve as a key IT advisor to the NIH Chief Information Officer.
A TOP SECRET security clearance will be required. More job detail is found at: http://www.jobs.nih.gov under the Executive Jobs section.Or contact Ms.Winnie Garner at seniorre@od.nih.gov. Applications must be received ELECTRONICALLY by (11:59 p.m.), December 17, 2008. DHHS and NIH are Equal Opportunity Employers

Bioinformatics Manager- Lilly Singapore Centre for Drug Discovery
For more information click here

Related Resources & Products

Part 11 and Drug Development: A Q&A Reference Guide (March, 2004)

HIPAA and Human Subjects Research: A Question & Answer Reference Guide (March 2003)

Good Clinical Practice: A Question and Answer Reference Guide 2003

Top Searches Bio-IT World CHI's Network

Medidata Solutions

Related Resources & Products

Cambridge Healthtech Institute